558 related articles for article (PubMed ID: 25886910)
21. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
[TBL] [Abstract][Full Text] [Related]
22. TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.
Yao H; Duan M; Lin L; Wu C; Fu X; Wang H; Guo L; Chen W; Huang L; Liu D; Rao R; Wang S; Ding Y
Oncotarget; 2017 Mar; 8(11):18337-18347. PubMed ID: 28407691
[TBL] [Abstract][Full Text] [Related]
23. Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells.
Lyu R; Zhu X; Shen Y; Xiong L; Liu L; Liu H; Wu F; Argueta C; Tan L
Epigenetics; 2022 Oct; 17(10):1180-1194. PubMed ID: 34689714
[TBL] [Abstract][Full Text] [Related]
24. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
25. Deletion of Tet proteins results in quantitative disparities during ESC differentiation partially attributable to alterations in gene expression.
Reimer M; Pulakanti K; Shi L; Abel A; Liang M; Malarkannan S; Rao S
BMC Dev Biol; 2019 Jul; 19(1):16. PubMed ID: 31286885
[TBL] [Abstract][Full Text] [Related]
26. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
[TBL] [Abstract][Full Text] [Related]
27. Dynamic switching of active promoter and enhancer domains regulates Tet1 and Tet2 expression during cell state transitions between pluripotency and differentiation.
Sohni A; Bartoccetti M; Khoueiry R; Spans L; Vande Velde J; De Troyer L; Pulakanti K; Claessens F; Rao S; Koh KP
Mol Cell Biol; 2015 Mar; 35(6):1026-42. PubMed ID: 25582196
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
[TBL] [Abstract][Full Text] [Related]
29.
Kunimoto H; McKenney AS; Meydan C; Shank K; Nazir A; Rapaport F; Durham B; Garrett-Bakelman FE; Pronier E; Shih AH; Melnick A; Chaudhuri J; Levine RL
Blood; 2017 Mar; 129(13):1779-1790. PubMed ID: 28077417
[TBL] [Abstract][Full Text] [Related]
30. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.
Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X
PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940
[TBL] [Abstract][Full Text] [Related]
31. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Inoue S; Li WY; Tseng A; Beerman I; Elia AJ; Bendall SC; Lemonnier F; Kron KJ; Cescon DW; Hao Z; Lind EF; Takayama N; Planello AC; Shen SY; Shih AH; Larsen DM; Li Q; Snow BE; Wakeham A; Haight J; Gorrini C; Bassi C; Thu KL; Murakami K; Elford AR; Ueda T; Straley K; Yen KE; Melino G; Cimmino L; Aifantis I; Levine RL; De Carvalho DD; Lupien M; Rossi DJ; Nolan GP; Cairns RA; Mak TW
Cancer Cell; 2016 Aug; 30(2):337-348. PubMed ID: 27424808
[TBL] [Abstract][Full Text] [Related]
32. PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.
Song C; Wang L; Wu X; Wang K; Xie D; Xiao Q; Li S; Jiang K; Liao L; Yates JR; Lee JD; Yang Q
Cancer Res; 2018 May; 78(10):2475-2489. PubMed ID: 29735542
[TBL] [Abstract][Full Text] [Related]
33. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
[TBL] [Abstract][Full Text] [Related]
34. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
[TBL] [Abstract][Full Text] [Related]
35. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
36. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
[TBL] [Abstract][Full Text] [Related]
37. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
38. TET2: A cornerstone in normal and malignant hematopoiesis.
Kunimoto H; Nakajima H
Cancer Sci; 2021 Jan; 112(1):31-40. PubMed ID: 33048426
[TBL] [Abstract][Full Text] [Related]
39. Region-Specific Methylation Profiling in Acute Myeloid Leukemia.
Cecotka A; Polanska J
Interdiscip Sci; 2018 Mar; 10(1):33-42. PubMed ID: 29405013
[TBL] [Abstract][Full Text] [Related]
40. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Moran-Crusio K; Reavie L; Shih A; Abdel-Wahab O; Ndiaye-Lobry D; Lobry C; Figueroa ME; Vasanthakumar A; Patel J; Zhao X; Perna F; Pandey S; Madzo J; Song C; Dai Q; He C; Ibrahim S; Beran M; Zavadil J; Nimer SD; Melnick A; Godley LA; Aifantis I; Levine RL
Cancer Cell; 2011 Jul; 20(1):11-24. PubMed ID: 21723200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
